US messenger RNA (mRNA) therapeutics and vaccines company Moderna (Nasdaq: MRNA) has announced an agreement in principle with the Australian government to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Victoria, Australia, including access to Moderna’s mRNA development engine.
The contemplated framework would build the foundation to support Australia with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vaccines in development for respiratory viruses. Moderna and the Australian government are committed to finalize the agreement.
Moderna expects that up to 100 million vaccine doses could be produced in Australia each year. The facility is intended to also be activated on an urgent basis to support Australia with direct access to rapid pandemic response capabilities. The company is in discussion with other governments about potential collaborations built on a similar model.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze